Copyright © Inderes 2011 - present. All rights reserved.

Stayble Therapeutics

0.25 SEK

-12.59 %

Less than 1K followers

STABL

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-12.59 %
+3.26 %
-27.47 %
-46.06 %
-50.29 %
-53.91 %
-93.60 %
-96.46 %
-96.61 %

Stayble Therapeutics operates in the pharmaceutical industry. The company specializes in research and development of injection treatments for pain caused by herniated discs. The drug candidates are developed and based on a proprietary technological platform. Most operations are found in the Nordic market and the company has its headquarters in Gothenburg.

Read more
Market cap
16.32M SEK
Turnover
80.14K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
25/2
2026

Annual report '25

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Stayble Therapeutics: Rapportkommentar Q2'25 - Kalqyl

Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust under det andra kvartalet. Nettoomsättningen uppgick till 0,0 MSEK (0,0), medan övriga rörelseintäkter landade på 0,0 MSEK (0,4). EBIT uppgick till -1,9 MSEK (-3,4). ...

Stayble Therapeutics
Third party research

Stayble Therapeutics: Rapportkommentar Q1'25 - Kalqyl

Stayble Therapeutics redovisade ingen nettoomsättning och en minskad rörelseförlust under det första kvartalet. Nettoomsättningen uppgick till 0,0 MSEK (0,0), medan övriga rörelseintäkter landade på 0,0 MSEK (0,0). EBIT uppgick till -2,1 MSEK (-3,9)....

Stayble Therapeutics
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.